Laurus Labs Ltd (LAUL)

Currency in INR
857.40
-4.60(-0.53%)
Real-time Data·
LAUL Scorecard
Full Analysis
Net income is expected to grow this year
LAUL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
855.05872.60
52 wk Range
427.05922.50
Key Statistics
Bid/Ask
857.55 / 858.00
Prev. Close
862
Open
864
Day's Range
855.05-872.6
52 wk Range
427.05-922.5
Volume
619.69K
Average Volume (3m)
2.39M
1-Year Change
88.19%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LAUL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
694.85
Downside
-18.96%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Laurus Labs Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Laurus Labs Ltd Company Profile

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Employees
6167
Market
India

Compare LAUL to Peers and Sector

Metrics to compare
LAUL
Peers
Sector
Relationship
P/E Ratio
91.5x27.8x−0.6x
PEG Ratio
0.370.580.00
Price/Book
10.4x2.8x2.6x
Price / LTM Sales
7.8x2.4x3.3x
Upside (Analyst Target)
−21.7%17.5%39.1%
Fair Value Upside
Unlock1.1%5.4%Unlock

Analyst Ratings

4 Buy
2 Hold
7 Sell
Ratings:
13 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 694.85
(-18.96% Downside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 9.46%
Dividend Yield
0.14%
Industry Median 0.74%
Annualised payout
1.20
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Jul 25, 2025
EPS / Forecast
3.00 / 2.11
Revenue / Forecast
15.70B / 14.45B
EPS Revisions
Last 90 days

LAUL Income Statement

People Also Watch

7,605.00
APLH
-1.59%
313.85
ETEA
-0.52%
278.15
ADTB
+0.25%
1,922.90
GLEN
-0.72%
369.30
BAJE
+1.50%

FAQ

What Stock Exchange Does Laurus Labs Trade On?

Laurus Labs is listed and trades on the India National Stock Exchange stock exchange.

What Is the Stock Symbol for Laurus Labs?

The stock symbol for Laurus Labs is "LAUL."

What Is the Laurus Labs Market Cap?

As of today, Laurus Labs market cap is 462.09B.

What Is Laurus Labs's Earnings Per Share (TTM)?

The Laurus Labs EPS (TTM) is 9.46.

When Is the Next Laurus Labs Earnings Date?

Laurus Labs will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is LAUL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Laurus Labs Stock Split?

Laurus Labs has split 1 times.

How Many Employees Does Laurus Labs Have?

Laurus Labs has 6167 employees.

What is the current trading status of Laurus Labs (LAUL)?

As of 29 Aug 2025, Laurus Labs (LAUL) is trading at a price of 857.40, with a previous close of 862.00. The stock has fluctuated within a day range of 855.05 to 872.60, while its 52-week range spans from 427.05 to 922.50.

What Is Laurus Labs (LAUL) Price Target According to Analysts?

The average 12-month price target for Laurus Labs is INR694.84615, with a high estimate of INR1025 and a low estimate of INR293. 4 analysts recommend buying the stock, while 7 suggest selling, leading to an overall rating of Neutral. The stock has an -18.96% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.